Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-1769

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 71335-1769). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Biso Api Structure (Api Pic New1)

Biso Api Structure (Api Pic New1)
Chemical structure of Bisoprolol Fumarate, depicting the molecular arrangement of bisoprolol with fumarate salt. The structure includes aromatic ring and functional groups characteristic of the compound.*
FDA Label Image

Hctz Api Structure (Api Pic New2)

Hctz Api Structure (Api Pic New2)
Chemical structure of Bisoprolol Fumarate and Hydrochlorothiazide showing a chlorinated benzene ring with sulfonamide and amino substituents, representing key functional groups of the active ingredients.*
FDA Label Image

1 (Table1 New)

1 (Table1 New)
A data table titled 'Sitting Systolic/Diastolic Pressure (BP) and Heart Rate (HR) Mean Decrease After 3 to 4 Weeks.' It compares blood pressure and heart rate changes for placebo and various dosages of Bisoprolol Fumarate and Hydrochlorothiazide across two studies, showing total blood pressure and heart rate decreases and drug effects in mm Hg and bpm.*
FDA Label Image

1 (Table 2new)

1 (Table 2new)
Data table showing the percentage of patients experiencing various adverse experiences categorized by body system during a clinical trial. It compares placebo and Bisoprolol Fumarate and Hydrochlorothiazide groups, with separate columns for all adverse experiences and drug-related adverse experiences, covering cardiovascular, respiratory, central nervous system, musculoskeletal, psychiatric, and gastrointestinal events.*
FDA Label Image

1 (Table 3new)

1 (Table 3new)
Table presenting serum potassium data from U.S. placebo-controlled studies comparing placebo, Bisoprolol Fumarate and Hydrochlorothiazide combinations at various doses, and hydrochlorothiazide 25 mg. It shows mean change in potassium (mEq/L) and incidence of hypokalemia (%) across study groups with respective sample sizes.*
FDA Label Image

Label (Lbl713351769)

Label (Lbl713351769)
Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide 5 mg/6.25 mg film coated tablets by Bryant Ranch Prepack. The label includes storage instructions at room temperature (20°-25°C), a note to keep drugs out of reach of children, and a bar code. It compares to Ziac 5/6.25 mg Tablet from Edenbridge Pharmaceuticals LLC and indicates a 30 count package.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.